February 8, 2021
For Immediate Release
Company name: | H.U. Group Holdings, Inc. |
Representative: | Shigekazu Takeuchi, Director, |
President and Group CEO | |
Securities code: | 4544 First Section, |
Tokyo Stock Exchange | |
Contact: | Atsuko Murakami, |
Executive Officer and CFO | |
Telephone No.: | +81-3-5909-3337 |
Notice of Revisions to the Full-Year Consolidated Earnings Forecasts for the Fiscal Year Ending
March 31, 2022
H.U. Group Holdings, Inc. (the "Company") hereby announces revisions to its full-year consolidated earnings forecasts for the fiscal year ending March 31, 2022 which the Company released on November 9, 2021. Details are as follows.
1. Revision to the full-year consolidated earnings forecast for the fiscal year ending March 31, 2022 (April 1, 2021
- March 31, 2022)
Profit | Earnings per | (Reference) | |||||||||||||||||
Net sales | Operating | Ordinary | attributable to | ||||||||||||||||
profit | profit | owners of | share | EBITDA※ | |||||||||||||||
(Million yen) | |||||||||||||||||||
(Million yen) | (Million yen) | parent | (Yen) | (Million yen) | |||||||||||||||
(Million yen) | |||||||||||||||||||
Previous Forecast (A) | |||||||||||||||||||
(Announced on | 254,700 | 35,500 | 33,700 | 23,500 | 411.97 | 50,700 | |||||||||||||
November 9, 2021) | |||||||||||||||||||
Revised forecast (B) | 267,300 | 44,000 | 42,500 | 27,000 | 473.92 | 58,500 | |||||||||||||
Change (B - A) | 12,600 | 8,500 | 8,800 | 3,500 | ― | 7,800 | |||||||||||||
Change (%) | 4.9 | 23.9 | 26.1 | 14.9 | ― | 15.4 | |||||||||||||
(Reference) Results for | |||||||||||||||||||
the previous fiscal year | 223,016 | 25,392 | 25,458 | 17,468 | 306.38 | 37,887 | |||||||||||||
(Fiscal year ended | |||||||||||||||||||
March 31, 2021) |
- EBITDA = Operating profit + Depreciation + Amortization of goodwill
2. Reasons for revisions to full-year consolidated earnings forecasts
In the third quarter under review, demand for COVID-19-related products in Japan and overseas, mainly in the IVD business, exceeded the forecast at the time of the announcement in November of the revisions to the full-year consolidated earnings forecasts for the fiscal year ending March 31, 2022.
In the fourth quarter of the current fiscal year, demand for tests and products related to COVID-19 is expected to exceed the forecast in the announcement in November due to the rapid increase in the number of new infections since January. In addition, some of the one-time costs related to the new central laboratory are expected to be carried over to the next fiscal year.
As a result, the Company revised its full-year consolidated earnings forecasts as above.
3. Dividend Forecast
There is no change to the year-end dividend forecast (63 yen per share) as a result of the latest revisions.
The earnings forecasts above have been prepared based on information available as of the date on which this material was announced. Actual results may differ due to a variety of factors going forward.